1

PUBLICATIONS

Primary Pharmacology Publications

- Berlanga J, *et al.* Wound healing promotion in rats treated with EGF is dose dependent. Biotecnol Apl. 1996;13:181-185. Available in https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/1996/13/3/p%20181%20-%20185.pdf.

- Berlanga J, *et al.* The effect of the EGF treatment schedule on the healing process of full-thickness wounds in pigs. Biotecnol Apl. 1997, 14:163-168. Available in https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/1997/14/3/163-168.pdf.

- Berlanga J, *et al.* Epidermal growth factor stimulated re-epithelialization in pigs: The possible role of acute wound proteases. Biotecnol Apl. 1998;15:83-87. Available in https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/1998/15/2/083-087.pdf.

- Prats PA, *et al.* Efecto del factor de crecimiento epidérmico sobre la regeneración del nervio ciático transectado en ratas. Biotecnol Apl. 1998;15:237-41. Available in https://tspace.library.utoronto.ca/html/1807/20232/ba98038.html.

Secondary Pharmacology Publications

- Berlanga J, et al. Epidermal growth factor protects against carbon tetrachloride-induced hepatic injury. Clin Sci (Lond). 1998;94(3):219-23. doi: 10.1042/cs0940219. Available in https://pubmed.ncbi.nlm.nih.gov/9616254/.
Caballero ME, et al. Epidermal growth factor (EGF) mediated prevention of renal ischemia/reperfusion injury. Biotecnol Apl. 2000;17:161-165. Available in https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2000/17/3/161-165.pdf.

- Calnan DP, et al. Potency and stability of C terminal truncated human epidermal growth factor. Gut. 2000;47(5):622-7. doi: 10.1136/gut.47.5.622. Available in https://pubmed.ncbi.nlm.nih.gov/11034576/.
Caballero ME, et al. Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut. 2001;48(1):34-40. doi: 10.1136/gut.48.1.34. Available in https://pubmed.ncbi.nlm.nih.gov/11115820/.

- Berlanga-Acosta J, et al. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut. 2001;48(6):803-7. doi: 10.1136/gut.48.6.803. Available in https://pubmed.ncbi.nlm.nih.gov/11358899/.

- Berlanga J, Lodos J, López-Saura P. Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents. Burns. 2002;28(5):435-42. doi: 10.1016/s0305-4179(02)00023-2. Available in https://www.sciencedirect.com/science/article/abs/pii/S0305417902000232.

- Berlanga J, et al. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am J Pathol. 2002;161(2):373-9. doi: 10.1016/S0002-9440(10)64192-2. Available in https://www.sciencedirect.com/science/article/pii/S0002944010641922.

- Sasaki M, et al. Keratinocyte growth factor and epidermal growth factor can reverse the intestinal atrophy associated with elemental diets in mice. Exp Physiol. 2003;88(2):261-7. doi: 10.1113/eph8802466. Available in https://physoc.onlinelibrary.wiley.com/doi/abs/10.1113/eph8802466.

- Prats PA, et al. Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds. Biopharm Drug Dispos. 2002;23(2):67-76. doi: 10.1002/bdd.299. Available in https://onlinelibrary.wiley.com/doi/abs/10.1002/bdd.299.

Heberprot-P

Para caminar por la vida

pasos seguros

2

PUBLICATIONS

Publications associated with medical indication

- Berlanga J, et al. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond). 2005;109(1):83-95. doi: 10.1042/CS20050026. Available in https://pubmed.ncbi.nlm.nih.gov/15755259/.
Berlanga J, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006;3(3):232-9. doi: 10.1111/j.1742-481X.2006.00237.x. Available in https://pubmed.ncbi.nlm.nih.gov/16984579/.

- Fernández-Montequín J, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-43. doi: 10.1111/j.1742-481X.2007.00344.x. Available in https://pubmed.ncbi.nlm.nih.gov/17953679/.

- Berlanga J, et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J. 2008;5(4):530-9. doi: 10.1111/j.1742-481X.2008.00457.x. Available in https://pubmed.ncbi.nlm.nih.gov/19006574/.

- Fernández-Montequín J, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67-72. doi: 10.1111/j.1742-481X.2008.00561.x. Available in https://pubmed.ncbi.nlm.nih.gov/19291119/.

- Berlanga-Acosta J, et al. Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009;6(5):331-46. doi: 10.1111/j.1742-481X.2009.00622.x. Available in https://pubmed.ncbi.nlm.nih.gov/19912390/.

- Berlanga J. Heberprot P: Experimental background and pharmacological bases. Biotecnol Apl. 2010;27:88-94. Available in https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2010/27/2/BA002702RV088-094.pdf or http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200002&script=sci_abstract&tlng=en.

- Berlanga-Acosta J, et al. Cellular and molecular insights into the wound healing mechanism in diabetes. Biotecnol Apl. 2010;27(4):255-261. Available in: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000400001&lng=es.

- Berlanga-Acosta J, et al. Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression. Journal of Carcinogenesis & Mutagenesis. 2011;02(01). DOI: 10.4172/2157-2518.1000115. Available in https://www.researchgate.net/publication/273359614_Epidermal_Growth_Factor_EGF_and_Platelet-Derived_Growth_Factor_PDGF_as_Tissue_Healing_Agents_Clarifying_Concerns_about_their_Possible_Role_in_Malignant_Transformation_and_Tumor_Progression.

- Berlanga-Acosta J. Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J. 2011 Dec;8(6):612-20. doi: 10.1111/j.1742-481X.2011.00840.x. Available in https://pubmed.ncbi.nlm.nih.gov/21910827/.

- Tuero A. Inhibition of A431 cells growth in vitro and in tumor grafts by Recombinant Human Epidermal Growth Factor. Effect on gene expression. Biotecnol Apl. 2012;29:(2-3).

- Camacho H, et al. Analysis of cell proliferation and gene expression profiles in Epidermal Growth Factor-treated tumor cell lines. Minerva Biotecnológica. 2013;25(1):43-54. Available in: https://www.minervamedica.it/en/journals/minerva-biotechnology-biomolecular-research/article.php?cod=R04Y2013N01A0043.

- Berlanga-Acosta J, et al. Detrimental impact of acute and chronic glucose burden in wound-healing cells: fibroblasts, myofibroblasts and vascular precursor cells. Biotecnol Apl. 2012; 29(4):208-17. Available in: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522012000400001&lng=es.

- Berlanga-Acosta J, et al. Expression of cell proliferation cycle negative regulators in fibroblasts of an ischemic diabetic foot ulcer. A clinical case report. Int Wound J. 2013;10(2):232-6. doi: 10.1111/j.1742-481X.2012.12000.x. Available in: https://pubmed.ncbi.nlm.nih.gov/23194110/.

- Berlanga-Acosta J, et al. Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing. Biomed Res Int. 2013;2013:256043. doi: 10.1155/2013/256043. Available in https://pubmed.ncbi.nlm.nih.gov/23484099/.
Berlanga J, et al. Heberprot-P: A Novel Product for Treating Advanced Diabetic Foot Ulcer. MEDICC Review. 2013;15(1): 11-15. Available in: https://mediccreview.org/wp-content/uploads/2018/04/mr_287.pdf.

- López-Saura PA, et al. Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers. Adv Pharmacoepidem Drug Safety. 2013;2:128. doi:10.4172/2167-1052.1000128. Available in: https://www.walshmedicalmedia.com/open-access/medical-practice-confirms-clinical-trial-results-of-the-use-of-intralesional-human-recombinant-epidermal-growth-factor-in-advanced-diabetic-foot-ulcers-2167-1052-2-128.pdf.

Heberprot-P

Para caminar por la vida

pasos seguros

3 PUBLICATIONS

Publications associated with medical indication

• Guillén I, et al. Molecular mechanisms involved in the inhibition of tumor cells proliferation exposed to elevated concentrations of the epidermal growth factor. Biotecnol Apl. 2013; 30(3):223-227. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522013000300008&lng=es.

• Mendoza-Marí Y, et al. Histological and Transcriptional Expression differences between Diabetic Foot and Pressure Ulcers. Journal of diabetes & metabolism. 2013(04):1-10. Available in: https://www.iomcworld.com/open-access/histological-and-transcriptional-expression-differences-between-diabetic-foot-and-pressure-ulcers-2155-6156.1000296.pdf.

• Berlanga-Acosta J, et al. Type 2 Diabetes Mellitus (T2DM): Biological Overview from Pathways to Organelles and its Translation toward a Torpid Wound Healing Process. J Diabetes Metab. 2013;4:285. doi:10.4172/2155-6156.1000285. Available in: https://www.iomcworld.com/open-access/type-2-diabetes-mellitus-biological-overview-from-pathways-to-organelles-2155-6156.1000285.pdf.

• Cabal Mirabal CA, et al. Quantitative Studies of Diabetic Foot Ulcer Evolution Under Treatment by Digital Stereotactic Photography. Journal of Diabetes Science and Technology. 2019;13(5):821-826. doi:10.1177/1932296819853843. Available in: https://pubmed.ncbi.nlm.nih.gov/31195816/.

• Berlanga-Acosta J, et al. Unexpected Traits In Diabetic Wound Healing. Emerging Role of Epigenetic Events: A comment. Clinical Research on Foot & Ankle. 2014;2:147. DOI: 10.4172/2329-910X.1000147. Available in: https://www.researchgate.net/publication/266851957_Unexpected_Traits_In_Diabetic_Wound_Healing_Emerging_Role_of_Epigenetic_Events_A_comment
.

• Mendoza-Marí Y, et al. High glucose burden inhibits EGFR/PI3K/AKT1/mTOR signaling pathway in cutaneous fibroblasts. Biotecnol Apl. 2014;31(4):285-90. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522014000400003&lng=es.

• Berlanga-Acosta J, et al. Torpid Diabetic Wound Healing: Evidence on the Role of Epigenetic Forces. Int J Diabetes Clin Res. 2015;2:020. Available in: https://clinmedjournals.org/articles/ijdcr/ijdcr-2-020.pdf.

• Cama VF, et al. Epidermal Growth Factor based Therapy Promotes Intracellular Trafficking and Accumulation of its Receptor in the Nucleus of Fibroblasts from Diabetic Foot Ulcers. J Diabetic Complications Med. 2016;1:111. DOI: 10.4172/jdcm.1000111. Available in: https://www.researchgate.net/publication/312516161_Epidermal_Growth_Factor_based_Therapy_Promotes_Intracellular_Trafficking_and_Accumulation_of_its_Receptor_in_the_Nucleus_of_Fibroblasts_from_Diabetic_Foot_Ulcers.

• Ojalvo AG, et al. Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. Int Wound J. 2017;14(1):214-225. doi: 10.1111/iwj.12592. Available in: https://pubmed.ncbi.nlm.nih.gov/27002919/.

• Berlanga-Acosta J, et al. Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome. Biomed Res Int. 2017;2017:2923759. doi: 10.1155/2017/2923759. Available in: https://pubmed.ncbi.nlm.nih.gov/28904951/.

• Montequin JF, et al. Intralesional and perilesional application of an epidermal growth factor (Heberprot-P) in diabetic foot ulcers. Part one. Angiol Sosud Khir. 2018;24(4):33-42. PMID: 30531767. Available in: https://pubmed.ncbi.nlm.nih.gov/30531767/.

• Berlanga-Acosta J, et al. Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis. Journal of Diabetes & Metabolism. 2018;9:7. DOI:10.4172/2155-6156.1000798. Available in: https://www.iomcworld.com/open-access/epidermal-growth-factor-therapy-impact-on-scar-tissue-resilience-of-diabetic-lower-limbs-ulcersan-enlightening-hypothesis-2155-6156-1000798.pdf.

• Berlanga-Acosta J, et al. Epidermal Growth Factor (EGF) intralesional infiltrations: From the bench to the diabetic ulcers cells. Integrative Molecular Medicine. 2019;6. DOI: 10.15761/IMM.1000354. Available in: https://www.oatext.com/epidermal-growth-factor-egf-intralesional-infiltrations-from-the-bench-to-the-diabetic-ulcers-cells.php.

• García-Ojalvo A, et al. Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds. Int Wound J. 2019;16(6):1294-1303. doi: 10.1111/iwj.13189. Available in: https://pubmed.ncbi.nlm.nih.gov/31429187/.

• Berlanga-Acosta J, et al. Epidermal Growth Factor in Healing Diabetic Foot Ulcers: From Gene Expression to Tissue Healing and Systemic Biomarker Circulation. MEDICC Rev. 2020;22(3):24-31. doi: 10.37757/MR2020.V22.N3.7. Available in: https://pubmed.ncbi.nlm.nih.gov/32812896/.

• Berlanga-Acosta JA, et al. Cellular Senescence as the Pathogenic Hub of Diabetes-Related Wound Chronicity. Front Endocrinol (Lausanne). 2020;11:573032. doi: 10.3389/fendo.2020.573032. Available in: https://pubmed.ncbi.nlm.nih.gov/33042026/.

• Berlanga-Acosta J, et al. Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. Front Endocrinol (Lausanne). 2020 Nov 5;11:560375. doi: 10.3389/fendo.2020.560375. Available in: https://pubmed.ncbi.nlm.nih.gov/33224105/.

• González-Bravo M, et al. Applying Quantitative Immunogold Labeling Distributions of Cellular Compartments in Immunoelectron Microscopy Images to the Study of EGFR Intracellular Signaling. Biomed J Sci & Tech Res 2020;26(3). DOI: 10.26717/BJSTR.2020.26.004352.

Heberprot-P

Para caminar por la vida

pasos seguros

4

PUBLICATIONS

Publications associated with medical indication

• Ferrer-Tasies L, et al. Recombinant Human Epidermal Growth Factor/Quatsome Nanoconjugates: A Robust Topical Delivery System for Complex Wound Healing. Adv. Therap. 2021;4, 2000260. DOI: https://doi.org/10.1002/adtp.202000260. Available in: https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202000260.

• Berlanga-Acosta J, et al. Intralesional Infiltrations of Cell-Free Filtrates Derived from Human Diabetic Tissues Delay the Healing Process and Recreate Diabetes Histopathological Changes in Healthy Rats. Frontiers in Clinical Diabetes and Healthcare. 2021;2. DOI: 10.3389/fcdhc.2021.617741. Available in: https://pubmed.ncbi.nlm.nih.gov/36994347/.

Chapters of books

• Schultz G, et al. Linking the Advanced Glycation Endproducts/Receptor for Advanced Glycation Endproducts Pathway in Diabetics with Inflammation and Topical Antiinflammatory Treatments of Chronic Wounds. Book Chapter: Chapter 44. Advances in Wound Care: Volume 1. January 2010, 248-252. Comprehensive Wound Center. The Ohio State University Medical Center. ISBN13: 978-1-934854-01-3 e ISBN: 978-1-934854-18-1. USA. Available in: https://www.liebertpub.com/doi/10.1089/9781934854013.248.

• Berlanga-Acosta J, et al. Biology of the diabetic wound. Book Chapter in Foot Ulcers: Causes, Diagnosis and Treatments. P. E. Overhaussen, Ed., Nova Science Publishers, Hauppauge, NY, USA, 2009. ISBN 9781607417996.

• López-Saura P, et al. Intralesional human recombinant Epidermal Growth Factor for the treatment of advanced diabetic foot ulcer: from pro-of of concept to confirmation of the efficacy and safety procedure. Book chapter. Ch. 12: Global Perspective on Diabetic Foot Ulcerations. Edited by Edited by Thanh Dinh. https://doi.org/10.5772/28150. Available in https://www.intechopen.com/chapters/24696.